403-15-6

Basic information

• Product Name: 4-FLUORO-3-METHYLBENZOIC ACID
• Synonyms: RARECHEM AL BO 2279;4-Fluoro-3-methylbenzoic acid, 97+%;4-Fluoro-m-toluic acid, 5-Carboxy-2-fluorotoluene;4-FLUORO-M-TOLUIC ACID;4-FLUORO-3-METHYLBENZOIC ACID
• CAS NO: 403-15-6
• Molecular Formula: C₈H₇FO₂
• Molecular Weight: 154.14
• EINECS: -0
• Product Categories: Fluorin-contained Benzoic acid series;C8;Carbonyl Compounds;Carboxylic Acids;Fluorine series
• Mol File: 403-15-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 164-168 °C(lit.)
• Boiling Point: 266.3 °C at 760 mmHg
• Flash Point: 114.9 °C
• Appearance: White to light yellow crystal powder
• Density: 1.258 g/cm³
• Vapor Pressure: 0.00434mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.21±0.10(Predicted)
• BRN: 1936531
• CAS DataBase Reference: 4-FLUORO-3-METHYLBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-METHYLBENZOIC ACID(403-15-6)
• EPA Substance Registry System: 4-FLUORO-3-METHYLBENZOIC ACID(403-15-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 403-15-6(Hazardous Substances Data)

Usage

Chemical Properties

White to light yellow crystal powder

Synthesis Reference(s)

Journal of Medicinal Chemistry, 21, p. 38, 1978 DOI: 10.1021/jm00199a007

InChI:InChI=1/C8H7FO2/c1-5-4-6(8(10)11)2-3-7(5)9/h2-4H,1H3,(H,10,11)/p-1

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 74-88-4 methyl iodide 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 124-38-9 carbon dioxide 
• 82297-89-0 (4-fluoro-3-methyl)phenylmagnesium bromide 
• 452-65-3 2,4-dimethylfluorobenzene 
• 396-85-0 4,4'-difluoro-3,3'-dimethyl-biphenyl 
• 369-32-4 1-(4-fluoro-3-methylphenyl)ethanone 
• 598-30-1 sec.-butyllithium 
• 594-19-4 tert.-butyl lithium 

Downstream Products

• 398-79-8 4-fluoro-3-methyl-benzoic acid phenyl ester 
• 847862-92-4 4-fluoro-3-ethylbenzoic acid 
• 180636-50-4 methyl 4-fluoro-3-methylbenzoate 
• 1437780-11-4 4-fluoro-5-methyl-2-nitrobenzoic acid 
• 1437780-12-5 methyl 4-fluoro-5-methyl-2-nitrobenzoate 
• 1037206-86-2 methyl 2-amino-4-fluoro-5-methylbenzoate 
• 1437780-13-6 methyl 2-bromo-4-fluoro-5-methylbenzoate 
• 1437780-14-7 2-(2-bromo-4-fluoro-5-methylphenyl)propan-2-ol 
• 1437780-15-8 1-bromo-2-(2-(ethoxymethoxy)propan-2-yl)-5-fluoro-4-methylbenzene 
• 1437780-16-9 2-(2-(2-(ethoxymethoxy)propan-2-yl)-5-fluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1437779-64-0 6-fluoro-3,3-dimethyl-5-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)benzo[c][1,2]oxaborol-1(3H)-ol 
• 1443256-95-8 N'-(4-fluoro-3-methyl-benzoyl)-hydrazinecarboxylic acid tert-butyl ester 
• 1344239-33-3 4-fluoro-3-methyl-benzoic acid hydrazide 
• 171050-00-3 4-fluoro-3-methylbenzoic acid tert-butyl ester 

Relevant articles and documents

Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors

Pim kinases are promising therapeutic targets for the treatment of hematological cancers. A potent Pim kinase inhibitor 7f, derived from meridianin C, was further optimized by the replacement of 2-aminopyrimidine with substituted benzene. The optimization of the C-3 and C-5 positions of indole yielded compound 43 with improved cellular potency and high selectivity against a panel of 14 different kinases.

Substituted 1,3-thiazole compounds, their production and use

(1) A 1,3-thiazole compound of which the 5-position is substituted with a 4-pyridyl group having a substituent including no aromatic group or (2) a 1,3-thiazole compound of which the 5-position is substituted with a pyridyl group having at the position adjacent to a nitrogen atom of the pyridyl group a substituent including no aromatic group has an excellent p38 MAP kinase inhibitory activity.

Bicyclic fibrinogen antagonists

PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;